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Purpose: Developmental screening is necessary to ensure that children are reaching 
appropriate developmental milestones at each age. According to the American 
Academy of Pediatrics (AAP), early identification of Developmental Disability (DD) is 
key to a child's well being. In Argentina, pediatricians are currently using the Prueba 
Nacional de Pesquisa (PRUNAPE), translated as The National Screening Tool, a 
pediatrician-administered screening tool that takes approximately 20 minutes to 
administer. Due to the high volume of patients seen by Argentine pediatricians, many 
do not have time to administer the PRUNAPE during a child' s appointment, limiting the 
number of children screened for DO. Parent-completed screening tools, such as the 
Ages and Stages Questionnaire - Third Edition (ASQ-3), may be a good alternative for 
Argentine pediatricians. The reported success and efficiency of the Spanish translation 
of the ASQ-3 in other Spanish-speaking countries make it a strong candidate to be used 
as a developmental screening tool in Argentina. 
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Method: The PRUNAPE was compared to the ASQ-3 through two different methods.  
First, the two screeners were compared across research and development, test structure, 
and ease of administration. Second, a study comparing the results of the two screeners 
was conducted in a large hospital in Argentina. Pass/fail rates for each child on the 
ASQ-3 and the PRUNAPE were recorded and results were analyzed for each individual 
domain of each test and for the tests as a whole.  
 
Results: The ASQ-3 requires significantly less administration and scoring time from a 
pediatrician and gathers more information across more domains of development than 
the PRUNAPE. Validation studies indicate that both tests are sensitive enough to 
identify children at-risk, but the ASQ-3 validation study was conducted on a much 
larger population. In the comparison study of the ASQ-3 and the PRUNAPE, there was 
no strong correlation between the pass/fail results of the two screeners, meaning that the 
two screeners did not identify the same children as at-risk for DD.  
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Background 
Developmental Delays and Early Intervention 
 The World Health Organization (WHO) reports that across the world 
approximately 5% of children, birth-14 years of age, have a moderate or severe 
disability (WHO, 2004). Young children with developmental delays constitute one part 
of this 5%. Developmental delay (DD) is defined by the American Academy of 
Pediatrics (AAP) as “the condition in which a child is not developing and/or achieving 
skills according to the expected time frame” (AAP, 2006, p. 406). Developmental 
delays that go undetected and untreated during early childhood can lead to behavioral 
and social problems, as well as academic failure later in life (AAP, 2006). For this 
reason, it is important that pediatricians screen young children for DD throughout early 
childhood so they can then be referred for further evaluation and receive early 
intervention if needed.  
 Importance of Standardized Developmental Screening  
The AAP defines developmental screening as a standardized tool that helps 
identify children who are at risk of DD (AAP, 2006). Developmental screening is 
necessary to ensure that children are reaching appropriate developmental milestones at 
each age. Pediatricians typically screen a child’s fine and gross motor, communication, 
personal-social, and cognitive skills in order to identify domains in which that child 
may be delayed in his/her development in comparison to other children his/her age.  
Fine motor development depends on the coordination of small muscle movements 
(often using the hand and fingers) and includes skills such as using scissors, picking up 
small items, and drawing. Gross motor development involves large muscle movement, 
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such as jumping and running. Communication development includes skills in both 
expressive and receptive language and speech sound production. Personal-social 
development pertains to how a child interacts with the environment around him or her, 
including skills in personal awareness and how a child engages with others. In young 
children, cognitive development is demonstrated through problem solving skills, 
including a child’s ability to find a hidden toy or solve a puzzle.  
Developmental screening can be conducted in multiple settings (such as a 
doctors office or a preschool) by numerous different professionals (such as 
pediatricians, teachers, or social workers).  When children are found to be at-risk, 
following developmental screening, they can be referred for further evaluation by 
qualified personnel, such as speech language pathologists (SLPs), physical therapists 
(PTs), early childhood educators (ECEs), or occupational therapists (OTs).  Further 
testing can identify the presence/absence of a delay or disorder and if necessary the 
child can receive early treatment. According to the AAP, early identification of DD is 
key to a child’s well being. The AAP has identified well-check appointments as the 
ideal time for children to be screened for DD. For this reason, the AAP established a 
policy in 2006 requiring pediatricians in the United States to administer screening tests 
at each child’s 9-, 18- and 30-month doctor’s appointments. Using this schedule for 
checkups, the AAP believes DDs will be identified earlier leading to “further 
developmental, and medical evaluation, diagnosis, and treatment, including early 
developmental intervention” (AAP, 2006, p. 405). 
Developmental screening can be accomplished through the use of a 
commercially developed screening instrument or through developmental surveillance.  
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Commercially developed screening instruments can be administered to children directly 
by qualified personnel (e.g., during a doctor’s visit) or can be completed by parents 
(e.g., prior to a doctor’s visit).  
Developmental surveillance. Many pediatricians rely on their expert opinion to 
screen their young patients’ development.  This technique is called developmental 
surveillance and is defined as “a flexible, continuous process whereby knowledgeable 
professionals perform skilled observations of children during the provision of health 
care” (Dworkin, 1993, p. 121). Developmental surveillance requires a pediatrician to 
hear parental concerns, gather relevant information about the child’s developmental 
history, observe the child, and share any concerns with other professionals. Surveillance 
relies heavily on a pediatrician’s training across developmental domains. During 
developmental surveillance, pediatricians can also use a checklist of developmental 
milestones while observing the child and speaking with the parents, to see which of the 
milestones the child has reached. However, these lists typically do not contain enough 
details specific to a child’s age, which may cause pediatricians to miss a child who is at 
risk for DD (Glascoe, 1993). Research has found that the use of developmental 
surveillance alone leads to a low detection rate, missing up to 45 percent of children 
who might benefit from early intervention (Aylward, 2009).  
Commercially-developed screeners.  Formal screenings using commercially 
developed instruments more accurately identify children at-risk for DD (Rydz, et al., 
2005).  Commercially available screening instruments provide pediatricians with a 
standardized instrument in which to judge development. These screeners provide 
pediatricians with a clear way to record and evaluate each child’s skills. It is important 
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that commercially-developed screeners accurately identify children at-risk.  The validity 
of screening instruments can be measured by their sensitivity and specificity rates. 
Sensitivity is the proportion of children who are identified by the developmental 
screener as at-risk for DD, who are then further evaluated and diagnosed with DD. 
Specificity is the proportion of children who are identified by the developmental 
screener as not being at-risk for DD, who are further assessed and found to be typically 
developing. Developmental screening instruments should have sensitivity and 
specificity rates above 70% (AAP 2006).  
Pediatrician-administered screeners. Pediatrician-administered screening 
instruments are done during a child’s well-check appointment. A pediatrician must be 
trained in the administration of the screening tool and have enough time during a child’s 
appointment to administer, score, and evaluate the screener in order to determine if a 
child is at risk for DD. Pediatrician-administered instruments should have specific 
guidelines for the administration of the test in order to ensure the reliability of the 
instrument.  
Parental questionnaires. According to a recent study, parent-completed 
questionnaires were found to be as accurate as pediatrician-administered screening tools 
because parents “can give accurate information about their child's development” (Rydz, 
et al., 2006, p. 1179). Parental questionnaires not only save pediatricians’ time, but can 
also give a pediatrician additional information provided through parent observations. 
Furthermore, this study demonstrated that majority of parents are willing to complete 
questionnaires (81% for the ASQ-3) (Rydz, et al., 2006).  
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The Ages and Stages Questionnaire- Third Edition (ASQ-3) is a frequently used 
parent-completed developmental screener. Parents fill out the screener and then 
pediatricians (or affiliated staff) score it. This questionnaire was developed at the 
University of Oregon and is now used both nationally and internationally. It is one of 
the developmental screeners approved by the AAP to monitor a child’s developmental 
progress in place of a pediatrician-administered developmental screening tool (AAP, 
2006). The ASQ-3 has been translated and adapted into a Spanish version that is now 
widely used across the United States, as well as in several other predominately Spanish-
speaking countries.  
Developmental Screening in Argentina 
The prevalence of DD in Argentina has not been reported, but the Argentine 
Society of Pediatrics (SAP) strongly recommends developmental screening (Salamanco, 
D’Anna, & Lejarraga, 2004). In Argentina, screening for DD is typically done during an 
appointment with a pediatrician or doctor. The healthcare system plays an important 
role in monitoring child development. The healthcare system is broken up into private 
and public institutions. Within these two sectors, Argentineans can choose to have their 
usual check-up appointments at free public health centers or free public hospitals. 
Citizens who go to private hospitals and health care centers pay using private insurance 
or “obras sociales”, an insurance that can be bought through different trade union 
organizations. In the Ciudad Autonoma de Buenos Aires (CABA), which includes the 
city of Buenos Aires and its suburbs, approximately 18% of checkups for children under 
the age of 4 are done at public institutions, while 80% are done at private clinics or 
hospitals (Ministerio de Desarrollo Social de la Nación & UNICEF, 2013).  
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The Argentine Society of Pediatrics recommends that a developmental screening 
tool be administered to children during check-ups twice before a child reaches the age 
of 5 in order to catch signs of early DD. La Prueba Nacional de Pesquisa (PRUNAPE), 
translated as The National Screening Tool, is a pediatrician-administered screening tool 
that is designed to be administered during a child’s well-check appointment (Lejarraga, 
Kelmansky, Pascucci,  & Salamanco, 2005). This is the only screening tool that has 
been tested and validated for use in Argentina.  
In a study done by UNICEF, roughly 86.7% of children under age 4 had 
attended an appointment with their pediatrician within the previous 6 months before 
filling out the questionnaire for UNICEF (Ministerio de Desarrollo Social de la Nación 
& UNICEF, 2013). This indicates that children are routinely being seen for well-check 
visits in Argentina. However, according to data collected by The World Bank, there are 
approximately 3.2 doctors per 1000 people in Argentina (World Bank, 2010). Given the 
high number of patients each pediatrician is assigned within this healthcare system, 
pediatricians must conduct brief consults with patients and often do not have 20 minutes 
to devote to administering the PRUNAPE. While there is no reported data on the use of 
the PRUNAPE in Argentina, according to Celina Lejarraga, a pediatrician involved in 
the development of the Cuestionario PRUNAPE Pre-Pesquisa (mentioned below), the 
PRUNAPE is being used in hospitals including the Hospital de Pediatría SAMIC Dr. 
Juan P Garrahan, Hospital Durand, Hospital Santojanni, Hospital de Niños Ricardo 
Gutierrez, and Hospital Italiano (C. Lejarraga, personal communication, April 24, 
2014). According to one of the pediatricians on the research team for this study, doctors 
who do not use the PRUNAPE are relying solely on developmental surveillance during 
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appointments to monitor a child’s development.  (T. Moro, personal communication, 
July 29, 2013).  
CPPP. Horacio Lejarraga, the author of the PRUNAPE, and other Argentine 
pediatricians have recognized that the training time and time required to administer the 
PRUNAPE may prove difficult for pediatricians working in programs that provide care 
for a large number of children (Lejarraga, et al., 2013). In December 2013, Lejarraga 
released a pre-screener, the Cuestionario PRUNAPE Pre-Pesquisa (CPPP), which was 
designed to be completed by parents and scored by their child’s pediatrician prior to the 
child’s visit. If the child fails the CPPP, then the doctor administers the PRUNAPE 
during the visit.   
Research Questions 
Given the importance of developmental screening, a solution must be created to 
ensure that Argentine children are screened when they are young without taking up too 
much of the busy pediatrician’s time. The aim of this study was to compare the ASQ-3 
to the PRUNAPE/CPPP in order to answer the following two research questions.  
1. How does PRUNAPE/CPPP compare to the ASQ-3 in terms of research and 
development, general structure (number of questions and type of questions), and 
ease of administration?  
2. How does the ASQ-3 compare to the PRUNAPE when implemented as a 
screening tool in a large city in Argentina? What is relation between: 
a.  the overall pass/no pass rates of the two screeners? 
b. the pass/no pass results for the individual domains of each screener? 
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Research Methodology 
Research Question 1:  Systematic Review 
 Information was collected about the three screening tools being compared in this 
study: the PRUNAPE, the Spanish translation of the ASQ-3, and the CPPP. When 
available, information was collected from screening tool manuals, as well as validity 
and reliability studies published in peer-reviewed journals.  Table 1 lists all the 
materials used to answer the first research question.  
Research and development. Each screener was evaluated across three different 
aspects of research and development; (a) sample population size; (b) sensitivity; (c) 
specificity. Information was found using the original research articles published about 
the PRUNAPE and the CPPP and the official screening manual of the ASQ-3. 
 Since the validity study for the ASQ-3 was done for the English version, validity 
studies of the Spanish translation of the ASQ-3 were also used for comparison. Three 
studies done in Spain, Chile, and the United States were examined. Conclusions of these 
studies were used to determine the accuracy of the Spanish translation of the ASQ-3.  
Structure. The test protocols were examined for structure.  The total numbers of 
items on each on each test as a whole, as well as the number of items per domain, were 
calculated. The types of items and questions that were asked on each screening tool 
were examined, comparing the detail and phrasing of each item or question. The 
individual questions on each screener were also examined to compare the questions that 
were asked on one instrument but not on the other, or if the questions appeared in one 
domain on one test, but in a different domain on another test.  
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Administration.  In order to determine which screening instrument takes less 
time to administer and score, a comparison of the reported administration and scoring 
time for each screening tool was done using data reported in the ASQ-3, CPPP and 
PRUNAPE validation studies and screening manuals.  
Table 1   
Materials used to answer research question 1 
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Research Question 2  
 Data for this part of the study was collected at a large private hospital in Buenos 
Aires, Argentina over a period of nine months. Researchers carried out a comparison 
study of the PRUNAPE and the Spanish translation of the ASQ-3 by administering both 
screeners to patients recruited in the pediatric section of the hospital. The CPPP was not 
developed and released at the time of this study so it was not included in the comparison 
of screeners.  The student researcher participated in the data collection for the first two 
months.  The research pediatricians continued the study for the remaining 7 months and 
emailed the data to the student researcher.  Although it was requested, some of the data 
requested by the student researcher was not received (see below).   
Participants. 
Fifty-four parents and guardians of children birth to 42-months of age were 
recruited to participate in this study. Parent and child demographics are reported in table 
2.  Before any testing occurred, research staff described the study, reviewed inclusion 
criteria, and obtained informed consent from parents.  Parents, who agreed to 
participate, were included if they had children within the age requirement (birth to 42-
months) and had the time to complete the screening tests. Parents were excluded if their 
children had an illness or a previous diagnosis of DD/ known developmental condition 
including:  
• Low birth weight (Intrauterine Growth Restriction or preterm infants) 
• Fetal exposure to toxins (infections, alcohol, drugs) 
• Birth asphyxia 
• Delay of growth in the first or second year of life 
• Central Nervous System infections 
• Malnutrition 
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• Sensory (vision, audition, tactile, olfactory, taste, proprioception, vestibular 
system) deficit 
• Risk established or child has already been diagnosed with disease that affects 
development 
• Genetic syndromes, preterm neonates, metabolic diseases, prenatal infections 
 
During the first two months of the study, parents were recruited in one of the 
following ways: 1) 15 parents were recruited in the waiting room while waiting for their 
well-check appointments at the hospital, 2) 6 parents were recruited by their 
pediatricians during their well-checks, 3) 15 parents were recruited by a pediatrician in 
a specialty clinic for children at-risk. No data was reported for the remainder of the 
study. 
Parents who were recruited in the waiting room were approached by the research 
team and asked the age of their child and if their child was born prematurely/had a 
known DD. If the child met the study qualifications, researchers then described the 
study and asked the parents to participate. Parents who agreed were then brought to a 
private clinic room for the administration of the ASQ-3 and the PRUNAPE.  
When recruiting participants during appointments, the pediatrician, either an 
active participant of the research team or a member of the hospital staff, would describe 
the study and ask parents if they would like to participate. If the pediatrician was a part 
of the research staff, they would then administer the PRUNAPE during the child’s 
appointment and afterwards send the parents to another room with the student 
researcher to complete the ASQ-3. Pediatricians who were not a part of the research 
team were made aware of the study and the participation requirements. They would 
identify potential participants during appointments and if the parents agreed to 
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participate, the pediatrician would send them to a room where a pediatrician on the 
research staff would administer the PRUNAPE and then parents would either fill out the 
ASQ-3 immediately or take it home to complete. 
The head pediatrician of this study also held appointments for children who had 
been previously identified by other pediatricians or preschool teachers as having the 
potential for DD. For simplicity, these appointments will be referred to as appointments 
in the specialty clinic. The head pediatrician administered the PRUNAPE during the 
specialty clinic appointment and then if the parents agreed to participate in the study, 
they either went to another room with the student researcher to fill out the ASQ-3 
immediately or took it home to complete.  
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Table 2 
Demographic information 
 Participants 
Child’s Gender  
Male 33 
Female 21 
Child’s age (m age = 16 mo.) 
1 – 2 mo. 30 days 
3 – 4 mo. 30 days  
5 – 6 mo. 30 days  
7 – 8 mo. 30 days  
9 – 9 mo. 30 days  
10 – 10 mo. 30 days  
11 – 12 mo. 30 days  
13 – 14 mo. 30 days  
15 – 16 mo. 30 days  
17 – 18 mo. 30 days  
19 – 20 mo. 30 days  
21 – 22 mo. 30 days 
23 – 25 mo. 15 days 
25 mo. 16 days – 28 mo. 15 days  
28 mo. 16 days – 31 mo. 15 days 
31 mo. 16 days – 34 mo. 15 days 
34 mo. 16 days – 38 mo. 15 days  
39  – 44 mo. 30 days  
 
2 
2 
5 
3 
4 
1 
6 
1 
4 
1 
1 
4 
4 
1 
5 
2 
1 
1 
Family Health Insurance  
Plan de Salud  28 
AMPER 4 
Poder Judicial 4 
Private 17 
             Not Reported  1 
  
Parent Education  
Post-secondary 29 
Incomplete Univ. Education 3 
High School 12 
Junior High 2 
             Not Reported  8 
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Research staff. 
The research staff consisted of five pediatricians (four female and one male) and 
one student researcher. All research pediatricians worked for the hospital and were 
trained in the administration of the PRUNAPE. The number of screenings administered 
for this study by each pediatrician during the first two months is reported below in 
Table 3.  The number of screenings administered for this study by each pediatrician for 
the remainder of the study was not reported.  
Table 3  
Number of screenings administered by pediatricians  
Pediatrician Number of screenings administered  
1 (Head Pediatrician)  15 
2  12 
3  5 
4  3 
5  2 
 
Study procedures. During the first two months, 30 parents/guardians completed the 
ASQ-3 at the hospital and were provided access to a kit full of any materials necessary 
to answer the questions on the ASQ-3.  The research staff was present to help parents 
with questions or concerns they had while filling out the questionnaire. Four 
parent/guardians decided to take it home to complete. Two of the parents brought the 
filled out form back to one of the hospital locations where a member of the research 
staff worked. One was called by the student researcher two weeks later and asked to 
verbally relay her answers for each domain of the ASQ-3. One questionnaire was never 
returned. The procedures for parents were not reported for the remainder of the study.   
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The ASQ-3 and the PRUNAPE were both scored according to the publisher’s 
directions and data were recorded for the screening instruments as a whole (pass/no 
pass) and also by domain (pass/no pass per developmental domain).   For the screener 
as a whole, a  “pass” meant that the child had passed all domains of the screener and 
therefore no additional testing was recommended.   A “no pass” meant that the child 
had not passed one or more domains of the screener and additional testing was 
recommended. Domain analysis varied since the ASQ-3 and the PRUNAPE have 
different domains and are scored differently. For the PRUNAPE, the number of failed A 
tasks and B tasks was recorded for each domain. For the ASQ-3, each domain was 
marked 0 (white/pass), 1 (black/fail), and 2 (gray/pass but needs close surveillance).  
Data analysis. Cohen’s Kappa was used to determine if the agreement between the 
two screeners was greater than that expected by chance. Cohen’s Kappa is presented by 
the following function:  
  
where k represents the total concordance between the two tests, Pr(a) is the total number 
of participants who had the same results from both screeners (ie., either passed or failed 
both tests). Pr(e) is found by adding the number of passes and no passes for each 
separate test and dividing that number by the total number of participants and then 
adding these two numbers together. An online computer software program was used 
(Graph Pad, available at http://graphpad.com/quickcalcs/kappa1.cfm) to calculate 
Cohen’s Kappa in order to reduce the chance of human error. A kappa of .6 - .8 is 
considered moderate, and an agreement above .8 is considered almost perfect agreement 
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and therefore acceptable for a screening tool (Landis, & Koch, 1977) A .8 means that 
80% of the agreement between the two items being compared is not due to chance and 
therefore is determined to be a strong agreement.  
Results 
Research Question 1 
 This section covers the data that was collected in the comparison of the research 
and development, administration, and structure of the PRUNAPE, ASQ-3, and CPPP.  
Research and development. 
PRUNAPE. The PRUNAPE was created based on a population of 329 healthy 
children who were evaluated in preschools and doctors’ offices in Argentina. The 
results from developmental evaluations of these children were used to determine the 
criteria for the cutoff point of the A and B milestones. The PRUNAPE has a format 
similar the pediatrician-administered Denver screening (Lejarraga, Kelmansky, 
Pascucci,  & Salamanco, 2005, p. 31). The PRUNAPE was then given to 106 children, 
ranging from 0 to 5.99 years of age. After administering the PRUNAPE to these 
children, the criteria for a pass or no-pass were determined by adjusting the children’s 
scores in order to find the point at which there was the highest sensitivity and specificity 
rates. After comparing the sensitivity and specificity of the test using just milestone B 
cutoffs, just milestone A cutoffs, and a combination of the two, Lejarraga settled on 
using 1-A or 2-B milestones that a child was unable to complete as the final criteria for 
the failing of the PRUNAPE. The focus was on having a high specificity rate, to ensure 
that the least amount of children possible with DD were missed. According to these 
cutoff rates, approximately 20% of the test population failed the screening (Lejarraga et 
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al., 2008). This screener has a reported sensitivity of 80% and specificity of 93% 
(Lejarraga, et al., 2005, p. 44). These results are shown in Table 4.  
CPPP. The CPPP was administered to a sample of 533 children (see Table 4) in 
Buenos Aires (Lejarraga., et al. 2013).  It was administered in two ways; parents either 
directly filled it out (CPPP-SA) or were asked the questions by a psychologist, 
educational psychologist or pediatrician (CPPP-HP). The respective rates for the CPPP-
SA and CPPP-HP showed a Cohen’s Kappa coefficient of .23 and .28 when compared 
with the PRUNAPE, a sensitivity rate of 41-43%, and a specificity: 81-85% (Lejarraga, 
et al. 2013 p. 476).   
ASQ-3. The ASQ-3 was originally validated using questionnaires received from 
a sample of 18,572 participants across the United States (see Table 4). Using this 
sample, researchers tested the ASQ-3 for test-retest reliability, interobserver reliability, 
internal consistency, and concurrent validity.  From this study, researchers determined 
that a cutoff point of 2 standard deviations below the mean resulted in the highest 
specificity and sensitivity rates across all the questionnaires. Using these cutoff points, 
the ASQ-3 has a specificity of 85% and a sensitivity of 86% (Squires, Bricker, 
Twombly, & Potter, 2009, p. 172). Researchers also determined a “monitoring zone” 
for children which fell between 1 and 2 standard deviations from the mean (Squires, et 
al., 2009, p. 170).  
The ASQ-3 has also been adapted, translated and tested in many other countries. 
In studies conducted in Norway, Finland, Quebec, Canada, South Africa, Korea, 
Turkey, India, Shanghai, Spain, the Netherlands, Brazil, Thailand, Chile, and Taiwan, 
the ASQ-3 has proved to have a high validity in each test population. The Spanish 
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translation of the ASQ-3 has been tested for accuracy in several Spanish-speaking 
populations, including Spanish-speaking families in the U.S. (Guiberson, & Rodriquez, 
2010; Pomés, 2012), upper-middle class families in Santiago, Chile (Schonhaut, 
Salinas, Armijo, Schönstedt, Álvarez, & Manríquez, 2009), and preschoolers in Galicia, 
Spain (Sarmiento, Squires, & Ponte, 2010). In the studies done with Spanish speakers in 
the U.S., Spain and Chile, the results show that the Spanish translation of the ASQ-3 is 
an accurate screening tool when used in different Spanish-speaking populations.  
Researchers, Sarmiento, Squires and Ponte, completed a study comparing results 
from the ASQ-3 used in the preschools in Galicia, Spain with those found in the United 
States and Norway. In a comparison of the sensitivity and specificity rates found in the 
study in Galicia and in the United States and Norway, the results showed that there was 
no difference between the two, meaning that the validity rates acquired for the screening 
tool when used in Galicia were just as high as when it was used in the U.S. From these 
results, the study determined that the Spanish translation of the ASQ-3 could be used as 
an effective and efficient screening tool in Galicia, Spain (Sarmiento, Squires, & Ponte, 
2010).  
Researchers in Chile conducted a study to determine if there was a strong 
correlation between the results from the ASQ-3 and the Bayley Scales of Infant 
Development (Bayley III) that was considered to be the gold standard of developmental 
testing, but a rather difficult tool to access in Chile. The study included a total of 306 
children attending a well-child clinic in Santiago, Chile. Parents filled out the ASQ-3 
and pediatricians administered the Bayley-III. With the participants in that study, the 
ASQ-3 had a sensitivity of 58.8% and a specificity of 87.2% and an overall agreement 
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of 56% with the Bayley Scales of Infant Development. Given the high specificity rate, 
and the time and cost limitations posed by the use of the Bayley-III, researchers 
concluded that the ASQ-3 be recommended for screening children at 8-, 18- and 30-
months of corrected gestational ages (Schonhaut, et al., 2009).  
The study done by Pomés on Spanish-speaking populations in the U.S. revealed 
that the majority of items on the Spanish-translation of the ASQ-3 could be understood 
and correctly evaluated by parents filling out the questionnaire (Pomés, 2012). Pomés 
found roughly approximately 30% of the questions asked on the Spanish translation of 
the ASQ-3, to function differently than on the English version of the ASQ-3, meaning 
that the question on the Spanish translation may not test the same skill that it tests on 
the English version. The study also showed 16 of the 180 items evaluated on the ASQ-3 
to be misfit items, items that were misrepresented on the Spanish translation. When 
interviewing parents who participated in the study, the majority responded that the 
Spanish translation was clearly written and easy to respond to and understand.   
Table 4 
Comparison of Ages and Stages Questionnaire – Third Edition (ASQ-3), Prueba Nacional 
de Pesquisa (PRUNAPE) and Cuestionario PRUNAPE Pre-Pesquisa – Self 
Administration/Health Professional (CPPP-SA/HP) in research and development. 
 
 PRUNAPE ASQ-3 CPPP-SA/HP 
Study Sample Population 106 18,572 533 
Sensitivity 80% 86% 41%/42% 
Specificity 93% 85% 81%/85% 
 
Administration. 
PRUNAPE. The PRUNAPE is administered by a pediatrician during a regularly 
scheduled appointment with the parent or caregiver present and takes approximately 20 
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minutes to administer and score. The pediatrician presents the child with certain 
developmental tasks and then observes the child to see if he or she can accomplish 
them. The pediatrician then scores the child’s performance on each task and adds up the 
total tasks that the child passed and failed.  
 CPPP. The CPPP is completed before a child’s well-check appointment by a 
parent or by another professional asking questions to a parent. Pediatricians score the 
questionnaire and then decide if they need to complete the PRUNAPE during the 
child’s visit.  If the child passes the CPPP, then the pediatrician doesn’t need to do take 
the time to do the PRUNAPE. The time required to administer and score the CPPP was 
not reported. 
ASQ-3. The ASQ-3 is filled out by parents and then scored by a pediatrician or 
someone else at the pediatrician’s office. The time required to score the ASQ-3 is 
between 2-5 minutes. Parents can fill out the ASQ-3 while sitting in a waiting room or 
can take the questionnaire home and send or bring it back in at a later time.  
Table 5 
Administration comparison across the Ages and Stages Questionnaire- Third Edition 
(ASQ-3),  Prueba Nacional de Pesquisa (PRUNAPE) and Cuestionario PRUNAPE Pre-
Pesquisa (CPPP).   
 
 ASQ-3 PRUNAPE CPPP 
Administration/ scoring 
time required by 
pediatricians 
2-5 min 20 min NR 
Person 
administering/completing 
screening questionnaire 
Parent/guardian  Pediatrician 
Parent/guardian 
or healthcare 
professional  
NR = Not Reported 
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Structure. 
PRUNAPE. The PRUNAPE measures 79 different developmental items that are 
grouped into four domains: personal-social, fine motor, language and gross motor (see 
Table 6). Each item is represented on the test by a bar that shows at which age 25%, 
50%, 75% and 90% of children have mastered that item (See Appendix A). The end of 
the bar represents 25%, 50% is represented by a tick mark at the top of the bar, 75% is 
represented by the left side of the shaded (gray) area, and 90% is represented by the 
right end of the bar. A child is scored pasa/pass (P), falla/fail (F), or rehúsa/no response 
or opportunity (R) according to the instructions given in the PRUNAPE manual. A line 
is drawn vertically on the form according to the child’s age. If the line crosses the bar in 
any zone to the left of 90%, this means that there is a percentage greater than 10% of 
normal children that can complete the item at older ages than the child being screened. 
An item in which the line passes to the right of the bar is called “Item A” and an item 
that crosses the bar between 75-90% is called “Item B”. For each domainn, the 
pediatrician tests each item where the line goes through the gray area of the bar, the “B 
Items”, as well as the three “Item A” tasks that appear closest to the left of the line.  
Most items must be demonstrated to the pediatrician during the child’s appointment. 
However, there are certain tasks, indicated by a * that can be marked according to 
answers given by parents. Items marked with the letter “M” are tasks that can be 
demonstrated by the pediatrician and items marked “2-4” are tasks that allow the child 
to make 2-4 additional attempts if they do not complete the task on the first try.  
CPPP. As noted in Table 6, the CPPP consists of five different questionnaires (each 
specific to a certain age range) that include questions pertaining to 57 of the 79 
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milestones listed on the PRUNAPE. The CPPP asks 14-16 questions for each age range, 
with all questions asked in one group rather than divided into different developmental 
domains. 
ASQ-3. The ASQ-3 is a parent-completed questionnaire covering five domains of 
development; fine motor, gross motor, language and communication, problem solving, 
and personal/social (see Table 6). There are 21 ASQ-3 questionnaires for children ages 
1-month to 5.5 years, at each of the following different age intervals:  2-, 4-, 6-, 8-, 9-, 
10-, 12-, 14-, 16-, 18-, 20-, 22-, 24-, 27-, 30-, 33-, 36-, 42-, 48-, 54-, and 60-months of 
age. A maximum of 10 points is assigned if a parent answers “sí/yes” to a question, 5 
points is assigned for “a veces/sometimes” and 0 points is assigned if a parent answers 
“no”. The total score is then filled in on a chart correlating with either the black (fail), 
grey (pass but needs close surveillance), or white section (pass). If a child scores in the 
black on any section, the child is at risk for development delay in that domain and fails 
the ASQ-3.  
Each ASQ-3 questionnaire asks a total of 30 questions, six per domain, for each 
age range (not including the general observation questions). The following is an 
example of the questions asked on the 2-month ASQ-3 questionnaire (see Appendix B) 
about a child’s fine motor skills (a child’s ability to grasp objects with his or her hands). 
“1) Cuando está despierta, ?su bebé usualmente tiene las manos cerradas? (Si antes las 
mantenía cerradas, pero ahora las abre, marque sí) “When awake, does your baby 
usually have his/her hands closed” (If he/she kept them closed before, but opens them 
now, mark yes” 2) Cuando Ud. toca con su dedo la palma de la mano de su bebé, ?le 
agarra su dedo? “When you touch your finger to the palm of your child’s hand, does 
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he/she grab your finger?” 3) Cuando Ud. pone un juguete en la mano de su bebé, ?lo 
sostiene por algunos instantes? “When you put a toy in your child’s hand, does he/she 
hold onto it for several seconds?” 4) Cuando está despierto, ?su bebe mantiene las 
manos abiertas, al menos parcialmente (en vez de tenerlas en puño, como cuando era 
recien nacido). “When awake, does your child keep his/her hands open, at least partially 
(instead of holding them in fists, like when he/she was a newborn)”.  
Table 6 
Structural comparison of the ASQ-3 (Ages and Stages Questionnaire-3rd Edition), 
PRUNAPE (Prueba Nacional de Pesqiusa) and CPPP (Cuestionario PRUNAPE Pre-
Pesquisa).  
 
 ASQ-3 PRUNAPE CPPP 
Number of domains   5 4 1 
Number of questions/items per 
domain 6 4 14-16 
Number of questionnaires 21 1 5 
Number of total tasks/questions 
asked per questionnaire 30 16 14-16 
Number of questions that were not 
included on the other screener*  132 15 15 
*the number of questions that were asked on the PRUNAPE that were not included on the ASQ-3 and 
the number of questions that were asked on the ASQ-3 that were not included in the PRUNAPE.  
 
 
Research Question 2 
 
The results corresponding to research question 2, comparing the PRUNAPE and ASQ-3 
in an Argentine population, are laid out in this section, including: the agreement of the 
overall results (Cohen’s Kappa), the agreement of the results for each individual domain 
on the screeners, the pass/fail rates divided up according to the administering 
pediatrician, and the agreement of the overall results given different cutoff points.  
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Overall Screener Agreement. Pass/fail rates for the PRUNAPE and the ASQ-3 
were analyzed.  The two screeners yielded the same results approximately 76% of the 
time (41/54 agreement). As shown in Table 7, this resulted in a Cohen’s Kappa of .47, 
which fell below the suggested .80 coefficient, indicating that there was not strong 
agreement between the two tests. Approximately 30 (55%) of the test results were 
determined to agree purely due to chance according to Cohen’s Kappa.  
Table 7 
Pass/Fail Results - Cohen’s Kappa 
K= 0.466 
Number of observed agreements: 41 (75.93% of the observations)  
Number of agreements expected by chance: 29.7 (54.94% of the observations)  
Further analysis of the results showed that of the participants who failed one 
screener but passed the other, neither screener showed a strong tendency to either pass 
or fail more children. Of the 13 tests that didn’t agree, six passed the PRUNAPE but 
failed the ASQ-3 and seven failed the PRUNAPE but passed the ASQ-3.  Overall, 25/54 
children failed either both or one of the screeners. This means that the failure rate for 
this study was 46%, just under half of the sample population. These results are shown in 
Figure 1. 
 
ASQ-3 (Ages and Stages 
Questionnaire – 3rd Edition) 
Pass 
ASQ-3 Fail 
T
o
t
a
l 
PRUNAPE (Prueba 
Nacional de Pesquisa) 
pass 
29 6 35 
PRUNAPE fail 7 12 9 
Total 36 18 54 
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Figure 1  
Overall Results 
 
 
 
 
 
 
 
 
 
While the agreement rate for the overall results was 76% and had a Cohen’s 
Kappa of .47, the agreement of the results for the participants screened by each 
pediatrician varied, as shown in Table 8. The head pediatrician working in the specialty 
clinic who had the most experience using the PRUNAPE had the highest screener 
agreement with 13 of the 15 screener results agreeing.  
 
Table 8 
Agreement results for each pediatrician  
 Agreement  Total  Percentage Cohen’s Kappa  
Pediatrician 1 13 15 87% .727 
Pediatrician 2 7 11 63% .241 
Pediatrician 3 3 5 60% .167 
Pediatrician 4  2 3 67% 0 
Pediatrician 5 0 2 0% 0 
 
29 
12 
6 
7 Passed PRUNAPE/PassedASQ-3
Failed PRUNAPE/Failed ASQ-
3
Passed PRUNAPE/Failed
ASQ-3
Failed PRUNAPE/Passed
ASQ-3
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As shown in Table 9, of the 15 participants who were recruited in the specialty 
clinic appointments, half of the group failed the PRUNAPE or both screeners. Two 
failed the PRUNAPE but passed the ASQ-3, five failed both screeners and eight passed 
both screeners.  Even though the specialty clinic was for children already suspected of 
having a DD, the failure rates through the specialty clinic were lower than those of as 
the failure rates through the hospital as a whole. 
Table 9  
Pass/Fail results for each pediatrician  
 Pass  % pass rate Fail % fail rate  
Specialty Clinic (Pediatrician 1) 8  53% 7  47% 
Pediatrician 2 5 45.5% 6 54.5% 
Pediatrician 3  2 40% 3 60% 
Pediatrician 4 2 67% 1 33% 
Pediatrician 5 0 0% 2 100% 
Overall  17 47% 19 53% 
 
Due to such a low agreement between the results of the two screeners, the data 
were reexamined to determine if agreement improved when ASQ-3 cutoffs were 
changed. When the cutoff point determining if a child failed the ASQ-3 was changed to 
include children who scored in the grey area (need surveillance), there was no change in 
agreement. These results are displayed in Figure 2. Overall, failing participants who 
scored in the grey area on the ASQ-3 resulted in nine additional no pass ratings; three 
failed both screeners, and six failed the ASQ-3 but passed the PRUNAPE.  This resulted 
in 38/54 agreement (70%) and a Cohen’s Kappa of .41, which fell below the suggested 
.80 coefficient indicating that there was not strong agreement between the two tests.  
The number of children who failed the ASQ-3 but passed the PRUNAPE changed from 
six to 15 with the new cutoff scores.  
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Figure 2 
Pass/Fail rates when using gray area of ASQ-3 as cutoff criteria 
 
 
 
 
 
 
 
 
 
 
 
Domain agreement. An individual domain analysis was conducted to determine 
if the overall screener disagreement was due to disagreement between the two screeners 
in a specific test domain. Results of this analysis are displayed in Table 9.  Two 
domains were identified as potential sources of disagreement.  The PRUNAPE failed 
more children in the language domain Four children failed the PRUNAPE language 
domain, but passed the ASQ-3, while the ASQ-3 failed only one child in the language 
domain who passed the PRUNAPE language domain Further analysis found that there 
were four language developmental milestone questions that were asked on the 
PRUNAPE, that were not asked on the ASQ-3. Three of the four questions were asked 
for children above 11-months, and the other was for child 1-month old or younger. The 
23 
15 
12 
4 Passed PRUNAPE/Passed
ASQ-3
Failed PRUNAPE/Failed
ASQ-3
Passed PRUNAPE/Failed
ASQ-3
Failed PRUNAPE/Passed
ASQ-3
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four children who failed the language domain of the PRUNAPE were all above 28-
months in age, and therefore were asked these questions that were not included in the 
ASQ-3.  
Data also showed that six children failed the ASQ-3 problem solving domain, 
but passed the PRUNAPE overall. The PRUNAPE does not have a problem solving 
domain. In a detailed analysis, it was found that only 8/ 44 ASQ-3 problem-solving 
questions (ages 0-42 months of age) were included in some other domain on the 
PRUNAPE. Five were included in the fine motor domain, one in the language domain 
and two in the personal/social domain. There were none included in the gross motor 
domain. When comparing the answers of the screeners of the six children who failed the 
problem solving domain of the ASQ-3 and also failed the PRUNAPE, there was not a 
specific domain in which the failures seemed to correlate. Three of the six children who 
failed the problem solving domain of the ASQ, also failed every other domain on the 
ASQ-3. The fourth child failed all the domains of the ASQ-3 excluding the gross motor 
domain, and the other two children failed just the problem solving domain and a 
combination of the problem solving and fine motor domains. Two of the children who 
failed all the domains of the ASQ-3, also failed a task in each domain of the 
PRUNAPE. The other children failed the PRUNAPE in various different domains.  
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Table 10  
 
Individual domain results (Numbers represent how many children failed a domain of 
one screener but passed the same domain of the other screener)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*the PRUNAPE has no problem solving domain 
 
Discussion 
 
While both the ASQ-3 and the PRUNAPE have high reported sensitivity and 
specificity rates (Lejarraga, et al., 2005, p. 44; Squires, et al., 2009, p. 172) the ASQ-3 
was validated using a much larger sample size, making it the stronger screener in terms 
of research and development. In addition, there have been numerous other studies done 
testing the validity of the English version of the ASQ-3 as well as multiple studies done 
supporting the ASQ-3 Spanish translation’s validity in several different countries. The 
studies done in Spain and the United States both reported high specificity and 
sensitivity rates (Sarmiento, Squires, & Ponte, 2010; Pomés, 2012), however it is 
important to note the low sensitivity rate found in the ASQ-3 study done in Chile 
(Schonhaut, et al., 2009). The low sensitivity rate signifies that there were a large 
number of children who were identified by the ASQ-3 as being at risk for DD who were 
later evaluated as developing normally. Based on this study, the ASQ-3 seems to over-
identify children within that population.  While it can be costly and time consuming to 
 
Prueba Nacional de 
Pesquisa (PRUNAPE)  
Ages and Stages 
Questionnaire 3-rd 
Edition (ASQ-3) 
Gross Motor 3 3 
Fine Motor 5 3 
Social  5 3 
Language  4 1 
Problem Solving  N/A* 6 
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have a screening tool that over-identifies, the main focus of the screener is to ensure that 
children with DD are not missed in the screening process, therefore a low sensitivity 
rate is preferable to a low specificity rate.  
The CPPP also demonstrates a low sensitivity rate. The CPPP has the same goal 
as the ASQ-3 of ensuring that no children with DDs are missed and not identified 
during the screening. However over-identification while using the CPPP means that the 
PRUNAPE must still be administered to a large portion of the children coming in for 
appointments.  
The CPPP also has a low Cohen’s Kappa when the pass and fail results are 
compared with the results of the PRUNAPE. While the CPPP was developed as a 
parental-questionnaire that would identify children needing a full screening using the 
PRUNAPE, the low Cohen’s Kappa coefficient indicates that the CPPP does not 
identify the same children as the PRUNAPE and therefore may not be the best indicator 
of children who may be at risk and should be screened using the PRUNAPE. The low 
sensitivity combined with the low Cohen’s Kappa of the CPPP means that the goal of 
the CPPP, to eliminate the number of PRUNAPE screenings that must be administered 
during a well-check appointment, may not be achieved with this pre-screener.  
The reported administration and scoring time required by a pediatrician using 
the ASQ-3 is much less than that required of the PRUNAPE and therefore the ASQ-3 
appears to be a better option for pediatricians who may not have time to administer a 
screening during an appointment. Because parents can fill out the form before the 
appointment, either at home or in the waiting room, the pediatrician is only required to 
score it (or oversee someone on staff who scores it) and then can spend the rest of the 
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appointment discussing the results of the screener with the parent and performing other 
necessary duties during the appointment.  
The comparison study of the two screeners in a large Argentine hospital 
revealed a poor correlation between the results of the ASQ-3 and the PRUNAPE, even 
when the cutoff points were adjusted for the ASQ-3. The disagreement between the 
results of the two screeners does not come as a surprise once one analyzes the two 
screeners in more detail. While both screeners tested the same developmental 
milestones overall, the format of the two screeners differed significantly, potentially 
causing the difference in children identified.  The ASQ-3 contains detailed questions 
covering more developmental domains. Tasks are simplified and separated out into 
behaviors that a parent can easily observe. The PRUNAPE uses milestones that a 
pediatrician can recognize and can then use to generalize a child’s ability to perform 
similar developmental tasks. The tasks on the PRUNAPE must be quick and relatively 
easy to observe in a clinical setting. While the ASQ-3 contains more detailed skill-based 
questions, the PRUNAPE focuses on more conceptual milestones. This requires 
pediatricians to be knowledgeable about development and relies on their ability to 
translate observable skills into milestone acquisition.  
On the CPPP, the grouping of the questions into consecutive questions rather 
than dividing them into separate developmental domains makes it more difficult for 
pediatricians to identify potential risk domains. The CPPP can identify if a child fails 
overall but does not specify which domains are problematic. If the CPPP was divided 
into separate developmental domains similar to the PRUNAPE, this may save 
pediatricians time when administering the PRUNAPE to children who failed the CPPP. 
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If running low on time during an appointment, the pediatrician could potentially just 
screen the domain that the child failed on the CPPP, rather than doing a full screening. 
Overall, the PRUNAPE and ASQ-3 appeared to differ the most in the language 
domain. This may be due to a difference in the questions asked in these domains for 
children at older ages. The questions included on the PRUNAPE that did not appear on 
the ASQ-3 tended to be the questions that the children failed. This discrepancy between 
the two screeners may have been one of the factors that contributed towards the 
tendency for older children to fail the language domain of the PRUNAPE but pass the 
same domain of the ASQ-3.  
Another reason for the disagreement between the different domains of the 
screener comes from the problem solving domain of the ASQ-3, which does not appear 
on the PRUNAPE. Children who failed this portion of the ASQ-3 therefore could not 
fail the same domain of the PRUNAPE because the questions for this domain were 
either not asked on the PRUNAPE or were included in other domains of the 
PRUNAPE, causing the child to fail a different domain on the PRUNAPE.  
It is important to consider the impact that having different pediatricians 
administer the PRUNAPE can have on the reliability of the screening tool. While there 
are specific guidelines for the administration and scoring of each item on the 
PRUNAPE provided during the training and in the PRUNAPE manual, this does not 
completely eliminate the subjectivity of the screening that comes from each individual 
pediatrician.  Several factors, such as the time since the pediatrician took the 
PRUNAPE training course, the number of PRUNAPE screenings a pediatrician 
administers a week, and their level of confidence in the administration of the 
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PRUNAPE, have the potential to affect the results of the screening. The head 
pediatrician of the research team had the most experience administering the PRUNAPE 
out of the research team members. Given his greater familiarity with the screening 
instrument, it is important to note that the agreement between the two screeners in his 
specialty clinic, a Cohen’s Kappa of .727, was significantly higher than the Cohen’s 
Kappa found using the overall results in the study.    His experience in administering the 
PRUNAPE may have contributed to this higher agreement. 
 The 46% failure rate found in this study is quite a bit higher than the average 
5% of children the World Health Organization reported as having a moderate or severe 
disability (WHO, 2004). While this high failure rate does not directly affect the 
comparison of the two screening tests, it is an important piece of information to note. 
When looking at individual test results, it was not evident that one test failed more 
children than the other. Of the results that disagreed, six children failed the ASQ-3 and 
seven failed the PRUNAPE. Therefore a higher tendency to fail children in one test 
over the other was ruled out as a possible cause for this high failure rate.   
The failure rate for children seen in the specialty clinic screened during the first 
two months of the study is equivalent to that of children recruited at well-visits and in 
the waiting room. The 46% failure rate of the specialty clinic is, in fact, below the 50% 
failure rate of the participants recruited during the first two months, and equal to the 
46% failure rate of the overall study. Given this data, the use of the specialty clinic to 
recruit participants cannot be considered a main cause of the high failure rate found in 
this study.  
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Implications for Pediatricians in Argentina  
 Screening for DD should be high priority for professionals working with young 
children. It is important that a formal screening tool is used to identify children who are 
at risk for DD because research indicates that professional surveillance alone can miss 
detecting almost half of children with DD (Aylward, 2009). Unless an alternative is 
created giving pediatricians more time with patients during an appointment, 
pediatricians should consider the use of parent-completed questionnaires. The CPPP 
was a solution to this problem, however, given the low sensitivity rate of CPPP, 
pediatricians would still have to administer the PRUNAPE to a large number of 
children. 
 Based on the comparisons between the ASQ-3 and the PRUNAPE in this study, 
the two screeners do not identify the same children as at-risk. The ASQ-3 has been 
tested in larger sample populations, has evidence of strong validity in various Spanish 
speaking populations, and is a more detailed screening tool. Therefore, while the results 
of the ASQ-3 do not agree with those of the PRUNAPE in this study, the ASQ-3 should 
still be considered for use by Argentine pediatricians and professionals working with 
young children.  Continued research to determine the sensitivity and specificity rates of 
the ASQ-3 within the Argentine population is recommended.   
Implications for Early Childhood Care Providers 
Another option for developmental screening lies in the preschool and daycare 
providers. Preschools and early childhood care centers can be helpful in assessing and 
identifying children who may be at risk for DD. According to a study done by UNICEF, 
roughly 20% of children under the age of 2 attend some sort of preschool or childcare 
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facility. The number grows to 50% at age 3 and then 76% at age 4.  Specifically in the 
region of the Ciudad Autonoma de Buenos Aires (CABA), 61% of children attend some 
sort of preschool (Ministerio de Desarrollo Social de la Nación, & UNICEF, 2013). The 
childcare and preschool programs in Argentina consist of; sectors of either the public or 
private educational systems, as a part of the municipal and state programs, or as private 
programs supported by communities and foundations. The UNICEF study reports that 
57% of children attend public preschool, while 42% attend a private daycare (Ministerio 
de Desarrollo Social de la Nación, & UNICEF, 2013).  
The use of the ASQ-3 and parental developmental questionnaires should be 
considered in preschools due to the high number of children attending preschools by the 
age of 4. Between developmental screening in well-check appointments and with 
children being screened at preschools, there is less of a chance of children being missed 
in the early identification of DD.  
Future Directions 
There still remains a critical need for a time-sensitive, cost-effective, valid and 
reliable screening tool to be used in Argentina. This study compared the PRUNAPE and 
Spanish translation of the ASQ-3 to determine if the two screeners identified the same 
children as at risk for DD. Given that the results disagreed, further work must be done 
in comparing these two instruments to determine which screening tool is better at 
correctly identifying children who are developing normally, and those who are at risk 
for DD. Due to the small sample size used in this study, it is important to consider that 
the results may have been different given a larger sample population. While the trend 
seems to lead towards a high disagreement between the two screeners, different 
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conclusions may be reached with a larger sample size. Given the different agreement 
results for each pediatrician in this study, further research should be done to examine 
the pass/fail rates of the participants in relation to the pediatricians, based on their 
training and amount of experience administering the PRUNAPE.   
Pediatricians and researchers must work together to either create or find a 
screening tool that has a high specificity and sensitivity rate for the Argentine 
population and is fast and efficient to administer/score. One path to this screening tool 
could be a continuation of this study. Using a larger sample size, future research using 
the ASQ-3 could include a continuation and follow-up with each of the participants 
after they have been developmentally evaluated. Using the results of these evaluations, 
a sensitivity and specificity rate could be calculated for both the ASQ-3 and PRUNAPE 
to determine which screener is the better tool to identify children who are at risk for 
DD.   
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Appendix A  
Prueba Nacional de Pesquisa (PRUNAPE) 
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Appendix B  
Ages and Stages Questionnaire-3rd Edition (ASQ-3) 2-month questionnaire  
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